Yousif Capital Management LLC Sells 27,558 Shares of Pfizer Inc. (NYSE:PFE)

Yousif Capital Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 3.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 691,106 shares of the biopharmaceutical company’s stock after selling 27,558 shares during the period. Yousif Capital Management LLC’s holdings in Pfizer were worth $19,897,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Briaud Financial Planning Inc acquired a new position in Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the third quarter worth approximately $34,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter worth about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Performance

Shares of PFE stock traded up $0.06 during trading hours on Tuesday, hitting $26.32. 24,286,365 shares of the company were exchanged, compared to its average volume of 42,105,117. The firm has a fifty day simple moving average of $27.07 and a 200 day simple moving average of $28.52. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The stock has a market capitalization of $149.04 billion, a price-to-earnings ratio of 73.11, a P/E/G ratio of 1.17 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 EPS. Research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.